Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.51 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.51 |
| ▸ | NADK | O95544 | 1/20 | 0.50 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.48 |
| ▸ | ADH1A | P07327 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22219802 | 0.96 | POLB (0.52) | POLBENPP1P2RY1NADKRNASEL | |
| SCHEMBL22220009 | 0.91 | RNASEL (0.45) | POLBNADKRNASELADH1A | |
| SCHEMBL31454757 | 0.86 | POLB (0.70) | POLBENPP1P2RY1RNASEL | |
| SCHEMBL29382612 | 0.86 | POLB (0.70) | POLBENPP1P2RY1RNASEL | |
| SCHEMBL22220015 | 0.84 | RNASEL (0.47) | POLBP2RY1RNASEL | |
| SCHEMBL20792516 | 0.83 | RNASEL (0.51) | NADKRNASEL | |
| SCHEMBL22219987 | 0.82 | POLB (0.43) | POLBENPP1P2RY1NADKADH1A | |
| SCHEMBL22219807 | 0.81 | POLB (0.42) | POLBENPP1P2RY1NADKADH1A | |
| SCHEMBL22219944 | 0.81 | POLB (0.51) | POLBENPP1P2RY1NADK | |
| SCHEMBL20691324 | 0.81 | RNASEL (0.46) | POLBP2RY1NADKRNASELADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947263-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200223883-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947263-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | POLB 32/4885ENPP1 44/4885P2RY1 725/4885 |
| US-20200223883-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | POLB 32/4885ENPP1 44/4885P2RY1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.